What Wall Street needs to hear from the Fed
What do investors need to hear from the Federal Reserve following its two-day policy meeting? Yahoo Finance's Seana Smith, Rick Newman and Dion Rabouin discuss.
Acacia says ZTE business to remain suspended until ban lifted
The Chinese company reached a $1.4 billion settlement with the Commerce Department, made public on Monday, to resume business with U.S. suppliers. ZTE said on Tuesday its shares would resume trading on the Hong Kong stock exchange on June 13 following its settlement with the United States. Acacia said the settlement may ultimately allow it to resume ties with ZTE.
Bipartisan Senate effort aims to override Trump’s deal to save ZTE
A bipartisan group of Senators has added language to the National Defense
The Truth Behind iQIYI, Inc’s Multibagger Potential
China internet stocks are hot. The likes of Alibaba Holdings Ltd (NYSE:BABA), Tencent Holding/ADR (OTCMKTS:TCEHY), Baidu Inc (ADR) (NASDAQ:BIDU) and others have rallied well over 100% over the past several years. But, as noteworthy as these stocks may be, iQIYI, Inc (NASDAQ:IQ) is one freshly public Chinese internet stock that has staged a 100%-plus rally in a much shorter time frame, and it is arguably the most talked about Chinese internet stock today.
GSK says vaccine business president to leave by year-end
Roger Connor, president of its global manufacturing and supply division since 2012, would replace Debruyne on September 1. Debruyne has held a number of roles during his career at GlaxoSmithKline, including general manager in the Netherlands and Italy and senior vice president of the company's pharmaceuticals business in Europe. CEO Emma Walmsley said earlier this year she was increasingly confident the company would be able to drive sales and profit growth over the next few years, helped by newer products such as its successful new shingles vaccine Shingrix.
Pump prices continue to retreat
Allergan's Second Anti-CGRP Drug Positive in Mid-Stage Study
Allergan's (AGN) anti-CGRP candidate, atogepant, successful in mid-stage study, following positive data readouts from two phase III studies on another anti-CGRP candidate, ubrogepant.